LabCorp to Host Investor and Analyst Day on February 27, 2018
February 20 2018 - 8:45AM
Business Wire
LabCorp® (NYSE: LH), a leading global life sciences company,
will host an Investor and Analyst Day for institutional investors
and financial analysts in New York City on Tuesday, February 27,
2018. The event, which will feature presentations by members of the
management team, begins at 8:30 a.m. ET and will conclude by
approximately 1:30 p.m. Prior registration is required to attend
the event.
All are invited to listen to the live event and view the
presentation slides via webcast on the LabCorp Investor Relations
website at www.labcorp.com. The audio portion of the presentation
is also available by dialing 844-634-1444 (615-247-0253 for
international callers). The access code is 4099115.
A replay of the webcast will be available following the
conclusion of the live event. To access the webcast recording,
visit www.labcorp.com. This webcast will be archived and accessible
through February 22, 2019.
About LabCorp
LabCorp (NYSE: LH), an S&P 500 company, is a leading global
life sciences company that is deeply integrated in guiding patient
care, providing comprehensive clinical laboratory and end-to-end
drug development services. With a mission to improve health and
improve lives, LabCorp delivers world-class diagnostic solutions,
brings innovative medicines to patients faster and uses technology
to improve the delivery of care. LabCorp reported net revenues of
over $10 billion in 2017. To learn more about LabCorp, visit
www.labcorp.com, and to learn more about Covance Drug Development,
visit www.covance.com.
Forward-Looking Statements
This press release contains forward-looking
statements including but not limited to statements with respect to
estimated 2018 guidance and the related assumptions, the impact of
various factors on operating and financial results, expected
savings and synergies (including from the LaunchPad initiative and
from acquisitions), and the opportunities for future growth. Each
of the forward-looking statements is subject to change based on
various important factors, including without limitation,
competitive actions and other unforeseen changes and general
uncertainties in the marketplace, changes in government
regulations, including healthcare reform, customer purchasing
decisions, including changes in payer regulations or policies,
other adverse actions of governmental and third-party payers,
changes in testing guidelines or recommendations, adverse results
in material litigation matters, the impact of changes in tax laws
and regulations, failure to maintain or develop customer
relationships, our ability to develop or acquire new products and
adapt to technological changes, failure in information technology,
systems or data security, employee relations, and the effect of
exchange rate fluctuations. Actual results could differ materially
from those suggested by these forward-looking statements. The
Company has no obligation to provide any updates to these
forward-looking statements even if its expectations change. Further
information on potential factors, risks and uncertainties that
could affect operating and financial results is included in the
Company’s Form 10-K for the year ended December 31, 2016, and
subsequent Forms 10-Q, including in each case under the heading
risk factors, and in the Company’s other filings with the SEC. The
information in this press release should be read in conjunction
with a review of the Company’s filings with the SEC including the
information in the Company’s Form 10-K for the year ended December
31, 2016, and subsequent Forms 10-Q, under the heading MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180220005589/en/
LabCorpInvestor Contact:Scott Frommer,
336-436-5076orMedia Contact:Pattie Kushner, 336-436-8263
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Apr 2023 to Apr 2024